Aldeyra Therapeutics (ALDX) Cash & Equivalents (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Cash & Equivalents data on file, last reported at $40.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 18.87% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (down 18.87% YoY) and the FY2025 annual result came in at $70.0 million, up 28.45% from the prior year.
• Cash & Equivalents retreated to $40.9 million in Q1 2026, from $70.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $165.0 million in Q1 2023 to a low of $14.3 million in Q4 2023.
• A 5-year average of $79.3 million and a median of $55.0 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 90.09% — and 2024, when it soared 280.97%.
• Tracing ALDX's Cash & Equivalents over 5 years: stood at $144.4 million in 2022, then sank by 90.09% to $14.3 million in 2023, then soared by 280.97% to $54.5 million in 2024, then increased by 28.45% to $70.0 million in 2025, then sank by 41.67% to $40.9 million in 2026.
• The last three Cash & Equivalents figures came in at $40.9 million (Q1 2026), $70.0 million (Q4 2025), and $55.0 million (Q3 2025), per Business Quant data.